G

    Genmab AS (GMAB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $33.16
    -0.07 (-0.21%)

    Market Cap: $20.42B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    59%(17/29)
    Avg Surprise
    +18.08%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$0.35
    Range$0.24 - $0.41
    5 analysts
    EPS Revisions
    2
    0
    7d
    2
    0
    30d
    EPS Estimate Drift
    90d ago$0.32-9.3%
    60d ago$0.31-11.5%
    30d ago$0.32-9.2%
    7d ago$0.35-1.2%
    Current$0.35
    Revenue Consensus
    $7.9B
    Range$7.5B - $9.5B
    10 analysts
    Dec 31, 2026
    EPS Consensus$0.23
    Range$0.23 - $0.23
    1 analysts
    Revenue Consensus
    $8.2B
    Range$7.0B - $9.1B
    17 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.23---
    Sep 26EST
    		-$0.35---
    Jun 26
    		$0.54$0.37+45.95%Beat+0.0%
    Mar 26
    		$0.13$0.19-31.58%Miss-58.1%
    Dec 25
    		$0.21$0.37-43.24%Miss-75.0%
    Sep 25
    		$0.65$0.45+44.44%Beat+124.1%
    Jun 25
    		$0.54$0.39+38.46%Beat+68.8%
    Mar 25
    		$0.31$0.23+34.78%Beat+6.9%
    Dec 24
    		$0.84$0.28+200.00%Beat+500.0%
    Sep 24
    		$0.29$0.33-12.12%Miss-37.0%
    Jun 24
    		$0.32$0.32+0.00%Beat+6.7%
    Mar 24
    		$0.29$0.14+107.14%Beat+480.0%
    Dec 23
    		$0.14N/A-53.33%Miss+7.7%
    Sep 23
    		$0.46$0.31+48.39%Beat-13.2%
    Jun 23
    		$0.30$0.29+3.45%Beat-25.0%
    Mar 23
    		$0.05N/A-66.67%Miss-50.0%
    Dec 22
    		$0.13N/A-60.61%Miss-23.5%
    Sep 22
    		$0.53$0.20+165.00%Beat+152.4%
    Jun 22
    		$0.40$0.20+100.00%Beat+400.0%
    Mar 22
    		$0.10$0.19-47.37%Miss-63.0%
    Dec 21
    		$0.17N/A-96.79%Miss+21.4%
    Sep 21
    		$0.21$0.13+59.70%Beat+61.5%
    Jun 21
    		$0.08$0.07+10.65%Beat-98.9%
    Mar 21
    		$0.27$0.23+17.39%Beat-10.0%
    Dec 20
    		$0.14N/A-89.06%Miss-95.9%
    Sep 20
    		$0.13N/A-86.87%Miss-89.4%
    Jun 20
    		$7.58$6.43+17.88%Beat+3690.0%
    Mar 20
    		$0.30$0.29+3.45%Beat+1604.5%
    Dec 19
    		$3.41$3.43-0.58%Miss+1568.3%
    Sep 19
    		$1.23$0.36+241.67%Beat+2708.2%
    Jun 19
    		$0.20$0.27-25.93%Miss+206.3%
    Mar 19
    		$0.02N/AN/ABeat-65.4%
    Dec 18
    		$0.20N/AN/ABeat-4.9%
    Sep 18
    		$0.04N/AN/ABeat+3228.6%
    Jun 18
    		$0.07N/AN/ABeat-16.4%
    Mar 18
    		$0.05N/AN/ABeat+1083.7%
    Dec 17
    		$0.21N/AN/ABeat+476.1%
    Sep 17
    		$-0.00N/AN/ABeat-103.1%
    Jun 17
    		$0.08N/AN/ABeat-
    Mar 17
    		$0.00N/AN/ABeat-
    Dec 16
    		$0.04N/AN/ABeat-
    Sep 16
    		$0.05N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio21.67EV/EBITDA19.33x
    Price/FCF23.59xFCF Yield4.24%
    Profitability
    Profit Margin19.10%Operating Margin35.20%
    ROE14.00%ROIC10.41%
    Financial Health
    Debt/Equity0.86xInterest Coverage4.93x
    Current Ratio2.46xQuick Ratio2.44x
    Trading Statistics
    Beta0.69Avg Volume2.87M
    52-Week High$35.4352-Week Low$23.62

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$33.55
    SMA 20$32.21
    SMA 50$29.78
    SMA 200$29.27
    EMA 10$33.21
    EMA 20$32.31
    EMA 50$30.38
    EMA 200$28.47

    MACD

    Line: 1.23Signal: 1.27Hist: -0.04

    ADX

    ADX: 32.3+DI: 34.8-DI: 22.3

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down12.0
    PSAR$34.44

    Bollinger Bands

    Upper Band$35.49
    Lower Band$28.92
    %B Position2040%(Upper)
    Band Width0.64

    RSI (14-Day)

    Neutral
    60.9

    Momentum Oscillators

    Stoch %K74.9
    Stoch %D81.8
    Williams %R-34.7
    ROC (10d)1.0%
    Momentum0.32
    CCI (20d)39.8
    MFI (14d)62.2

    Volatility Measures

    ATR (14d)$0.85(2.6%)
    StdDev (20d)1.64
    Hist Vol32.4%(Moderate)

    Volume Flow

    VWAP$32.99
    OBV15.4M
    AD Line64.4M
    CMF (20d)0.300

    Volume Metrics

    Avg Vol (20d)2.9M
    Vol Ratio0.6x
    VWMA (20d)$32.25

    Pivot Points

    R3$34.55
    R2$34.24
    R1$33.73
    Pivot Point$33.42
    S1$32.92
    S2$32.61
    S3$32.11

    Advanced Oscillators

    TSI36.71
    Ultimate Osc59.6
    KST149.66

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.16B$899.32M$1.05B$1.02B$924.81M$105.23M$6.44B$5.54B$779.00M$603.00M$4.68B$4.71B
    Cost of Revenue$84.00M$65.24M$80.76M$58.00M$56.99M$6.18M$337.00M$273.00M$28.00M$27.00M$126.00M$79.00M
    Gross Profit$1.07B$834.08M$974.05M$964.00M$867.82M$99.05M$6.10B$5.27B$751.00M$576.00M$4.55B$4.63B
    Operating Expenses$664.00M$608.24M$731.79M$505.00M$507.89M$71.38M$3.94B$3.17B$515.00M$460.00M$2.88B$2.95B
    R&D$459.00M$441.63M$524.41M$357.00M$363.92M$52.84M$2.66B$2.28B$361.00M$335.00M$1.95B$2.09B
    SG&A$205.00M$166.00M$208.00M$148.00M$144.00M$126.00M$1.25B$865.00M$894.00M$857.00M$934.00M$839.00M
    Operating Income$407.00M$225.83M$242.27M$459.00M$359.92M$27.67M$2.16B$2.10B$236.00M$116.00M$1.67B$1.69B
    Interest Income$36.00M$14.00M$48.00M$32.00M$25.00M$33.00M$224.00M$162.00M$292.00M$295.00M$295.00M$243.00M
    Interest Expense$110.00M$112.41M$43.87M$3.00M$9.00M$735,900$54.00M$18.00M$19.00M$4.00M$6.00M$8.00M
    Income Before Tax$295.00M$74.27M$54.83M$482.00M$422.91M$35.91M$3.60B$1.72B$307.00M$249.00M$926.00M$2.67B
    Income Tax Expense$-8,000,000$21.08M$23.93M$81.00M$86.98M$7.21M$-243,000,000$453.00M$104.00M$57.00M$286.00M$566.00M
    Net Income$303.00M$53.20M$30.91M$401.00M$335.93M$28.70M$3.85B$1.27B$203.00M$192.00M$640.00M$2.10B
    EBITDA$431.00M$186.69M$98.70M$503.00M$447.91M$39.00M$2.35B$2.20B$324.00M$266.00M$992.00M$2.76B
    EBIT$405.00MN/AN/A$485.00M$431.91M$36.65M$2.27B$2.12B$310.00M$253.00M$932.00M$2.68B
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about GMAB

    News

    Genmab stock steady as executives line up September investor conference appearances

    Genmab stock saw a modest decline on August 25, 2026, despite the company announcing its executives will participate in three major healthcare investor conferences in September 2026. These appearances in Boston, New York City, and London will provide investors with updates on Genmab's growth strategy, financial performance, and pipeline developments. The upcoming conferences are expected to be key in shaping investor sentiment regarding the antibody specialist's future.

    Ad-hoc-news.de•8/25/26•
    Neutral

    Genmab to Participate in Upcoming Investor Conferences

    Genmab A/S announced that members of its Executive Committee will participate in several investor conferences in September 2026. These include the Wells Fargo 21st Annual Healthcare Conference, the 24th Annual Morgan Stanley Global Healthcare Conference, and the Bank of America Global Healthcare Conference. Webcasts of these presentations will be available on Genmab’s investor relations website.

    The Manila Times•8/25/26•
    Neutral

    Genmab to Participate in Upcoming Investor Conferences

    Genmab A/S announced its participation in three investor conferences in September 2026. Members of its Executive Committee will present at the Wells Fargo 21st Annual Healthcare Conference, the 24th Annual Morgan Stanley Global Healthcare Conference, and the Bank of America Global Healthcare Conference. Webcasts of these presentations will be available on Genmab's website.

    GlobeNewswire•8/25/26•
    Neutral

    Genmab A/S (GMAB): Analyst Ratings Signal 16% Upside Potential In Biotech Growth Play

    Genmab A/S (GMAB), a Danish biotechnology company focused on antibody-based cancer treatments, is drawing significant investor interest with its robust product pipeline and strategic partnerships. Analysts have given GMAB an overwhelming "buy" rating, projecting a 16.10% upside potential with an average target price of $38.84. The company demonstrates strong financial health with a 24.90% revenue growth rate, 14.00% return on equity, and $870.6 million in free cash flow, underscoring its capacity for continued innovation and market expansion.

    DirectorsTalk Interviews•8/24/26•
    Bullish

    Genmab stock holds firm as royalties and pipeline draw eyes

    Genmab's stock remains stable due to its significant royalty income, particularly from DARZALEX sales, and a strong product pipeline. The company's valuation, including a 2026 P/E ratio of 21.5x, is closely tied to its ability to maintain and grow these revenue streams. Investors are focusing on future operating updates and royalty flows to justify its current market position.

    Ad-hoc-news.de•8/22/26•
    Bullish

    Frequently Asked Questions About GMAB

    Does GMAB pay dividends?
    Genmab AS (GMAB) does not currently pay a regular dividend.
    What is GMAB's P/E ratio?
    Genmab AS has a price-to-earnings (P/E) ratio of 21.67.
    What is GMAB's market cap?
    Genmab AS (GMAB) has a market capitalization of $20.42B with a current stock price of $33.16.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In